REG - Hikma Pharmaceutical - Outcome of Audit Tender Process

Hikma PharmaceuticalsAnnouncement

07/11/2024 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241107:nRSG4195La&default-theme=true

RNS Number : 4195L  Hikma Pharmaceuticals Plc  07 November 2024

Hikma Pharmaceuticals PLC

Outcome of Audit Tender Process

 

LONDON, 7 November 2024 - Hikma Pharmaceuticals PLC ('the Company' or 'Hikma')
announces that, following the completion of a formal competitive audit tender
process, the Board of Directors has approved the reappointment of
PricewaterhouseCoopers LLP ('PwC') as the external auditor of Hikma from 2026
onwards.

As a UK public interest entity, Hikma is required to carry out an audit tender
every 10 years and rotate the external auditor every 20 years. We disclosed in
our 2023 Annual Report & Accounts the intention to commence an audit
tender, given PwC were initially appointed for the audit of the 2016 Annual
Report & Accounts.

Further details of the audit tender process will be included in our 2024
Annual Report & Accounts. This appointment is subject to shareholder
approval at the 2026 Annual General Meeting.

 

- ENDS -

Enquiries

 

 Hikma Pharmaceuticals PLC

 Helen Middlemist           +44 20 7399 2760

 Group Company Secretary

 

About Hikma

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,100 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com (http://www.hikma.com)

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)

(LEI: 549300BNS685UXH4JI75)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUBUVRSBUARAA